Medical Devices & Tech

BioNanomatrix, Inc.

3701 Market Street, 4th Floor
Philadelphia, PA 19104 USA
Phone
Fax
Click for website

Research Sector Medical Devices & Tech

Summary Description Develops single-molecule analysis systems for applications in molecular biology, biomedical research, diagnostics and personalized medicine.

Management Edward L. Erickson, President and CEO; Han Cao, Founder and Chief Scientific Officer; Michael Kochersperger, Vice President, Engineering; Lorraine LoPresti, Vice President, Finance & Administration and Chief Financial Officer; Gary Zweiger, Vice President, Business Development

Click here for Financial Data
Keywords: single molecule analysis, genome, genomics, DNA, assembly, mapping, structural variation, molecular diagnostics, personalized medicine

Comment


Updated: Aug. 22, 2013


Description

BioNanomatrix is developing pioneering nanoscale imaging and analytic platforms designed to dramatically reduce the time and cost needed to analyze the genome. Until now, whole genome analysis has bee......view more

Products / Services

Fundamentally, our products and business model are based on the classic razor/razorblade concept. Placements of our analysis platform, the nanoAnalyzer 1000 in customer sites coupled with application......view more

Technology / Differentiation

Our product offerings are based on systems consisting of our disposable nanochannel chip, reagents, analysis instrumentation, associated software, and standards/controls. The nanochannel chip is at th...view more

Market / Customers

We believe that our total available market is very large and can be segmented by: 1) type of customer -- academic and research institutions, enterprise customers (such as pharmaceutical, biotech and d......view more


Competitors / Substitutes / Alternatives

The field of single-molecule analysis is emerging and a number of smaller companies are developing single-molecule analysis products and service offerings for life science customers. Additionally, lar...view more

Strategy

Our strategy is to exploit opportunities in large genome centers initially and develop applications, such as DNA sample quality analysis, mapping and assembly and structural variation analysis that se...view more

Revenue / Funding

We have received approximately $23 million in funding to date consisting of venture capital, grant funding and a limited amount of bank debt....view more

Status

We are preparing to ship systems to selected external sites for beta testing beginning Q3 2010 and begin limited commercial release before the end of this year....view more

RELATED COMPANIES



    0000-00-00-5364